Skip to search formSkip to main contentSkip to account menu

Hasford Score

Known as: Hasford 
A method for assessing prognosis for patients with chronic myeloid leukemia. Patients are classified as a high, medium, or low risk on the basis of… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience
The Sokal, Hasford, and EUTOS scores were established in different treatment eras of chronic myeloid leukemia (CML). None of them… 
2014
2014
Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib
The third generation tyrosine kinase inhibitor (TKI) ponatinib extends the therapeutic armamentarium for the management of… 
Review
2014
Review
2014
Impact of risk score calculations in choosing front‐line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase
The approval of multiple tyrosine kinase inhibitors targeting BCR‐ABL has broadened the number of available therapeutic options… 
2012
2012
The predictive value of the Sokal and Hasford scoring systems in chronic myeloid leukaemia in the imatinib era.
Objectives: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by the presence of Philadelphia… 
Highly Cited
2011
Highly Cited
2011
European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation.
TO THEEDITOR: In 1984, Sokal et al 1 developed a scoring system to predict the outcome of patients with chronic myeloid leukemia… 
2011
2011
Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION.
6510 Background: In the randomized phase III DASISION trial of dasatinib v IM in newly diagnosed CML-CP, dasatinib showed higher… 
2010
2010
Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III…
LBA6500 Background: Dasatinib is a highly potent BCR-ABL kinase inhibitor. Once daily dasatinib demonstrated high rates of… 
Review
2005
Review
2005
Measuring and monitoring quality-of-life in population surveys: Still a challenge for public health research
Monitoring the health status o f the population is one o f the main activities in public health research. In the past years a… 
2004
2004
The German competence network ‘Acute and chronic leukemias’
R Hehlmann, U Berger, C Aul, Th Büchner, H Döhner, G Ehninger, A Ganser, N Gökbuget, D Hoelzer, K Überla, W Gassmann, WD Ludwig… 
2001
2001
Validation of the Hasford score in a demographic study in chronic granulocytic leukaemia
Chronic granulocytic leukaemia (CGL) is a rare disease. For most patients the only curative treatment (an allogeneic stem cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)